Literature DB >> 11317249

Recurrent nonmenstrual toxic shock syndrome: clinical manifestations, diagnosis, and treatment.

M M Andrews1, E M Parent, M Barry, J Parsonnet.   

Abstract

We report 3 cases of recurrent nonmenstrual toxic shock syndrome (TSS) and review the clinical manifestations, diagnosis, and treatment. The primary sites of infection were the genital tract (in a patient who underwent cesarean delivery), the upper respiratory tract, and a breast abscess. In all 3 patients, the initial illness was not recognized to be TSS; only after development of recurrent illness with desquamation was this diagnosis entertained. Strains of Staphylococcus aureus that were isolated from 2 patients produced TSS toxin-1, whereas the third strain produced staphylococcal enterotoxin B. All 3 patients lacked antibody to the implicated toxins at the time of presentation with recurrent illness. Nonmenstrual TSS can occur in a variety of clinical settings and may be recurrent. The presence of desquamation during a febrile, multisystem illness could suggest this diagnosis and should prompt the clinician to obtain appropriate cultures for S. aureus.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11317249     DOI: 10.1086/320170

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  15 in total

Review 1.  Antistaphylococcal vaccines and immunoglobulins: current status and future prospects.

Authors:  Stan Deresinski
Journal:  Drugs       Date:  2006       Impact factor: 9.546

2.  HLA class I-associated expansion of TRBV11-2 T cells in multisystem inflammatory syndrome in children.

Authors:  Rebecca A Porritt; Lisa Paschold; Magali Noval Rivas; Mary Hongying Cheng; Lael M Yonker; Harsha Chandnani; Merrick Lopez; Donjete Simnica; Christoph Schultheiß; Chintda Santiskulvong; Jennifer Van Eyk; John K McCormick; Alessio Fasano; Ivet Bahar; Mascha Binder; Moshe Arditi
Journal:  J Clin Invest       Date:  2021-05-17       Impact factor: 14.808

3.  Antibody responses in patients with invasive Staphylococcus aureus infections.

Authors:  G Jacobsson; P Colque-Navarro; E Gustafsson; R Andersson; R Möllby
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-04-10       Impact factor: 3.267

4.  Safety and Immunogenicity of a Parenterally Administered, Structure-Based Rationally Modified Recombinant Staphylococcal Enterotoxin B Protein Vaccine, STEBVax.

Authors:  Wilbur H Chen; Marcela F Pasetti; Rajan P Adhikari; Holly Baughman; Robin Douglas; Jill El-Khorazaty; Nancy Greenberg; Frederick W Holtsberg; Grant C Liao; Mardi K Reymann; Xiaolin Wang; Kelly L Warfield; M Javad Aman
Journal:  Clin Vaccine Immunol       Date:  2016-12-05

Review 5.  Toxic shock syndrome in children: epidemiology, pathogenesis, and management.

Authors:  Yu-Yu Chuang; Yhu-Chering Huang; Tzou-Yien Lin
Journal:  Paediatr Drugs       Date:  2005       Impact factor: 3.022

6.  Bacterial Toxins-Staphylococcal Enterotoxin B.

Authors:  Bettina C Fries; Avanish K Varshney
Journal:  Microbiol Spectr       Date:  2013-12

7.  New insights into the prevention of staphylococcal infections and toxic shock syndrome.

Authors:  Ying-Chi Lin; Marnie L Peterson
Journal:  Expert Rev Clin Pharmacol       Date:  2010-11-01       Impact factor: 5.045

8.  Staphylococcal enterotoxin B in vivo modulates both gamma interferon receptor expression and ligand-induced activation of signal transducer and activator of transcription 1 in T cells.

Authors:  R Plaza; J L Rodriguez-Sanchez; C Juarez
Journal:  Infect Immun       Date:  2006-10-30       Impact factor: 3.441

9.  Inhibition of toxic shock by human monoclonal antibodies against staphylococcal enterotoxin B.

Authors:  Eileen A Larkin; Bradley G Stiles; Robert G Ulrich
Journal:  PLoS One       Date:  2010-10-11       Impact factor: 3.240

10.  A murine model of ulcerative colitis: induced with sinusitis-derived superantigen and food allergen.

Authors:  Ping-Chang Yang; Chang-Sheng Wang; Zi-Yuan An
Journal:  BMC Gastroenterol       Date:  2005-03-03       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.